drugset / Trial / NCT00636636

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00636636 ↗

Phase 3 Completed 452 enrolled Depomed
RandomizedParallel-groupDouble-blindTreatment

Summary

Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control. The purpose of this study is to determine whether a new gabapentin tablet, which only needs to be taken once a day, is safe and effective for the treatment of postherpetic neuralgia.

Timeline

Start
2008-03
Primary completion
2009-08
Completion
2009-09

Outcome

Met primary endpoint

registry analysis (superiority or other test); G-ER vs Placebo; p = 0.0125; Least squares mean difference -0.49 (95% CI -0.88 to -0.11); ANCOVA NCT00636636 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Unknown 1800 mg —